SCHEMBL23748189

SCHEMBL23748189

C=CCOc1cccnc1C(O)c1ccccc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.44
HPGD P15428 2/20 0.43
TSHR P16473 1/20 0.43
MAPK1 P28482 1/20 0.43
HSD17B10 Q99714 1/20 0.43
ADRB2 P07550 2/20 0.43
ADRB1 P08588 2/20 0.43
SLC22A1 O15245 1/20 0.43
CYP1A2 P05177 1/20 0.43
HTR1A P08908 1/20 0.43
CYP2D6 P10635 1/20 0.43
HTR2A P28223 1/20 0.43
SLC6A4 P31645 1/20 0.43
ADRA1A P35348 1/20 0.43
LIG1 P18858 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.39
ADRB3 P13945 1/20 0.37
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
CHRNB2 P17787 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24353683 0.82 TSHR (0.40) LMNAHPGDTSHRMAPK1HSD17B10
SCHEMBL23748235 0.80 DRD2 (0.52) LMNAHPGDTSHRMAPK1HSD17B10
SCHEMBL24834940 0.76 SMN1; SMN2 (0.43) LMNAHPGDTSHRMAPK1HSD17B10
SCHEMBL1631946 0.76 MAPT (0.39) LMNAHPGDTSHRMAPK1HSD17B10
SCHEMBL23748151 0.75 GAA (0.52) LMNAHPGDTSHRMAPK1HSD17B10
SCHEMBL23748266 0.73 MAPT (0.44) LMNAHPGDTSHRMAPK1HSD17B10
SCHEMBL23748186 0.73 MAPT (0.44) LMNAHPGDTSHRMAPK1HSD17B10
SCHEMBL23748225 0.72 ADRB2 (0.39) LMNAHPGDTSHRMAPK1HSD17B10
SCHEMBL23748213 0.72 LIG1 (0.43) LMNAHPGDTSHRMAPK1HSD17B10
Hydrochloric Acid SCHEMBL9814568 0.72 TSHR (0.39) LMNAHPGDTSHRMAPK1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230002409-A1 MACROCYCLIC FLU ENDONUCLEASE INHIBITORS JANSSEN BIOPHARMA INC (US) 2023-01-05 US disclosed
US-20230002409-A1 MACROCYCLIC FLU ENDONUCLEASE INHIBITORS JANSSEN BIOPHARMA INC (US) 2023-01-05 US disclosed
US-11312727-B1 Macrocyclic flu endonuclease inhibitors Janssen Biopharma, Inc. (US) 2022-04-26 US disclosed
US-11312727-B1 Macrocyclic flu endonuclease inhibitors Janssen Biopharma, Inc. (US) 2022-04-26 US disclosed
EP-3864020-A1 MACROCYCLIC FLU ENDONUCLEASE INHIBITORS Janssen BioPharma, Inc. (US) 2021-08-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230002409-A1 MACROCYCLIC FLU ENDONUCLEASE INHIBITORS ACE, PNP, FEN1 LMNA 1057/4885HPGD 1171/4885TSHR 2251/4885
US-11312727-B1 Macrocyclic flu endonuclease inhibitors ACE, FEN1, PNP LMNA 965/4885HPGD 1024/4885TSHR 2179/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.